Daré Bioscience wins new U.S. patent for topical lopinavir-ritonavir HPV formulation
Patent protection is expected to extend into at least 2039. The program is in a Phase 2 trial in about 100 women, with topline results expected in 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.